Drug treatment of depression in HIV-positive patients: Safety considerations

Drug Safety

Volumn 28, Issue 9, 2005, Pages 753-762

  Pieper, Andrew A ^a   Treisman, Glenn J ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIRETROVIRUS AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; DOXEPIN; ESCITALOPRAM; FEMOXETINE; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; IMIPRAMINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AKATHISIA; ANOREXIA; ANORGASMIA; APPETITE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DELIRIUM; DEMENTIA; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISTRESS SYNDROME; DRUG FATALITY; DRUG SAFETY; DYSTHYMIA; ERECTILE DYSFUNCTION; GASTROINTESTINAL MOTILITY; HALLUCINATION; HEART ARRHYTHMIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSIVE CRISIS; IMPOTENCE; INSOMNIA; INTOXICATION; LIBIDO DISORDER; LIVER FAILURE; LIVER TOXICITY; MAJOR DEPRESSION; MEDICAL PROFESSION; MOOD DISORDER; NAUSEA; NEUROPATHY; NONHUMAN; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIST; RESTLESSNESS; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SYMPTOMATOLOGY; VIRUS REPLICATION; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTI-HIV AGENTS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HIV SEROPOSITIVITY; HUMANS; MONOAMINE OXIDASE; SAFETY; SEROTONIN UPTAKE INHIBITORS;

EID: 26444605856     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200528090-00002     Document Type: Review

References (95)

1. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58: 721-8
2. Kilbourne AM, Justice AC, Rabeneck L, et al. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001; 54 Suppl. 1: S22-8
3. Lyketsos CG, Hutton H, Fishman M, et al. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS 1996; 10: 1033-9
4. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725-30
5. Dew MA, Becket JT, Sanchez J, et al. Prevalence and predictors of depressive, anxiety and substance use disorders in HIV infected and uninfected men: a longitudinal evaluation. Psychol Med 1997; 27: 395-409
6. Dimatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 2000; 160: 2101-7
7. Lenz G, Demal U. Quality of life in depression and anxiety disorders: an exploratory follow-up after intensive cognitive-behavior therapy. Psychopathology 2000; 33: 297-302
8. Meltzer-Brody S, Davidson JR. Completeness of response and quality of life in mood and anxiety disorders. Depress Anxiety 2000; 12 Suppl. 1: 95-101
9. Holmes J, House A. Psychiatric illness predicts poor outcome after surgery for hip fracture: a prospective cohort study. Psychol Med 2000; 30: 921-9
10. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8: 261-9
11. Hays RD, Kravitz RL, Mazel RM, et al. The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study. J Behav Med 1994; 14: 88-90
12. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 1446-74
13. Leserman J, Jackson ED, Petitto JM, et al. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med 1999; 61: 397-406
14. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003; 54: 295-306
15. Stein MD, Solomon DA, Herman DS, et al. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry 2003; 160: 1659-62
16. Riley ED, Wu AW, Perry S, et al. Depression and drug use impact health status among marginally housed HIV-infected individuals. AIDS Patient Care STDS 2003; 17 (8): 401-6
17. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA 2001; 285 (11): 1466-74
18. van Servellen G, Chang B, Garcia L, et al. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 2002; 16 (6): 269-81
19. Tresiman GJ. AIDS education for psychiatrists. Prim Psychiatry 1999; 6: 71-3
20. Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav 2003; 7 (2): 101-8
21. Treisman G, Fishman M, Schwartz J, et al. Mood disorders in HIV infection. Depress Anxiety 1998; 7 (4): 178-87
22. Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001 Sep 15; 33 (6): 847-56
23. Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drugs 1999; 58: 1099-135
24. Rachlis A, Fanning MM. Zidovudine toxicity: clinical features and management. Drug Saf 1993; 8: 312-20
25. Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101: 34-40
26. McDaniel JS, Purcell DW, Farber EW. Severe mental illness and HIV-related medical and neuropsychiatric sequelae. Clin Psychol Rev 1997; 17: 311-25
27. Lyketsos CJ, Fishman M, Hutton H, et al. The effectiveness of psychiatric treatment for HIV-infected patients. Psychosomatics 1997; 38: 423-32
28. Lyketsos CG, Hoover DR, Guccione M, et al. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry 1996; 153 (11): 1430-7
29. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry 2002; 24: 43-7
30. Katon W. The epidemiology of depression in medical care. Int J Psychiatry Med 1987; 17: 93-112
31. Schulberg HC, Block MR, Madonia MJ, et al. The usual care of major depression in primary care practice. Arch Fam Med 1997; 6: 334-9
32. Perez-Stable E, Miranda J, Munoz R, et al. Depression in medical outpatients: under-recognition and misdiagnosis. Arch Intern Med 1990; 150: 1083-8
33. Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med 2003; 18 (6): 450-60
34. Perkins DO, Leserman J, Stern RA, et al. Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry 1995; 155 (12): 1776-81
35. Pugh K, Riccio M, Jadresic D, et al. A longitudinal study of the neuropsychiatric consequences of HIV-1 infection in gay men. II: Psychological and health status at baseline and at 12-month follow-up. Psychol Med 1994; 24: 897-904
36. Lyketsos CG, Hanson A, Fishman M, et al. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med 1994; 24: 103-13
37. Treisman G, Fishman M, Lyketsos C, et al. Evaluation and treatment of psychiatric disorders associated with HIV infection. Res Publ Assoc Res Nerv Ment Dis 1994; 72: 239-50
38. Lyketsos CG, Treisman GJ. Psychiatric disorders in HIV-infected patients. CNS Drugs 1995; 4: 195-206
39. Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994; 151: 516-23
40. Grassi B, Gambini O, Garghentini G, et al. Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Pharmacopsychiatry 1997; 30 (2): 70-1
41. Cazzullo CL, Bessone E, Bertrando P, et al. Treatment of depression in HIV-infected patients. J Psychiatry Neurosci 1998; 23 (5): 293-7
42. De Wit S, Cremers L, Hirsch D, et al. Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. J Int Med Res 1999; 27 (5): 223-32
43. Kristiansen JE, Hansen JB. Inhibition of HIV replication by neuroleptics agents and their potential use in HIV infected patients with AIDS related dementia. Int J Antimicrob Agents 2000; 14 (3): 209-13
44. Treisman GJ, Angelino AF. The Psychiatry of AIDS: a guide to diagnosis and treatment. Chapter 2: HIV and major depression. Baltimore (MD): The Johns Hopkins University Press, 2004
45. Elliott AJ, Uldall KK, Bergam K, et al. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive patients. Am J Psychiatry 1998; 155 (3): 367-72
46. Zisook S, Peterkin J, Goggin KJ, et al. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 1998; 59 (5): 217-24
47. Rabkin JG, Wagner G, et al. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999; 156: 101-7
48. Rabkin JG, Wagner G, Rabkin R. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry 1994; 55: 92-7
49. Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry 1994; 55: 433-9
50. Ferrando SJ, Rabkin JG, deMoore GM, et al. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry 1999; 60: 741-6
51. Rothschild AJ. New directions in the treatment of antidepressant-induced sexual dysfunction. Clin Ther 2000; 22 Suppl. A: A42-A51; discussion A58-61
52. Woodrum ST, Brown CS. Management of SSRI-induced sexual dysfunction. Ann Pharmacother 1998; 32: 1209-15
53. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997; 16 (6): 374-90
54. Younai FS, Marcus M, Freed JR, et al. Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 629-36
55. Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: improvement in affective and somatic symptoms. Gen Hosp Psychiatry 1997; 19: 89-97
56. Elliott AJ, Russo J, Bergam K, et al. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999; 60: 226-31
57. Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000; 20: 265-7
58. Hesse LM, von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001; 29: 100-2
59. Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003; 17: 638-40
60. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry 1995; 25: 53-67
61. Wagner GJ, Rabkin JG, Rabkin R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997; 42: 407-11
62. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61: 436-40
63. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psych 1983; 40: 1335-42
64. Neirenberg AA, Price LH, Charney DS, et al. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990; 18: 167-75
65. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634-40
66. Katona CLE, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80-6
67. Ogura C, Okuma T, Uchida Y, et al. Combined thyroid (triiodo-thyronine)- tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974; 28: 179-86
68. Joffe RT, Levitt AJ, Bagby M, et al. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 1993; 163: 574-8
69. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-4
70. Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psy-chiatry 1997; 154: 37-43
71. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58: 16-21
72. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://hivatis.org [Accessed 2001 Jan 1]
73. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the Internation-al AIDS Society-USA Panel. JAMA 2000; 283: 381-90
74. Tseng AL, Foisy MM. Significant interactions with new antire-trovirals and psychotropic drugs. Ann Pharmacother 1999; 33: 461-73
75. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2003; 16: 1201-15
76. Dresser GK, Spence JD, Bailey DG. Pharmocokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38 (1): 41-57
77. Ouellet D, Hsu A, Qian J, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998; 42 (12): 3107-12
78. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25 (4): 1200-10
79. DeSilva KE, LeFlore DB, Marston BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15: 1281-5
80. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43 (4): 414-22
81. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections: studies with neuropsychologic testing and magnetic resonance imaging [published erratum appears in Ann Intern Med 1988, 108 (3): 496]. Ann Intern Med 1987; 107: 828-36
82. Van Gorp WG, Satz P, Hinkin C, et al. The neuropsychological aspects of HIV-1 spectrum disease. Psychiatr Med 1989; 7: 59-78
83. McArthur JC, Sacktor N, Selnes O. Human immunodeficiency virus-associated dementia. Semin Neurol 1999; 19: 129-50
84. Low-Beer S, Chan K, Yip B, et al. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000; 23: 295-301
85. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled trial. N Engl J Med 1987; 317: 185-91
86. Blum MR, Liao SH, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85: 189-94
87. Maxwell S, Scheftner WA, Kessler HA. Manic syndrome associated with zidovudine treatment [letter]. JAMA 1988; 259: 3406-7
88. Wright JM, Sachdev PS, Perkins RJ, et al. Zidovudine-related mania. Med J Aust 1989; 150: 339-41
89. O'Dowd MA, McKegney FP. Manic syndrome associated with zidovudine [letter]. JAMA 1988; 260: 3587-8
90. SUSTIVATM (efavirenz) capsules [US prescribing information]. Wilmington (DE): DuPont Pharmaceuticals Company, 2000
91. Colebunders R, Verdonck K. Reply to Gonzalex and Everall. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs [letter]. AIDS 1999; 13: 869
92. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-73
93. Moyle G. Efavirenz: practicalities, considerations and new issues. Int J Clin Pract Suppl 1999; 103: 30-4
94. Hawkins T, Grossman D, Haubrich R. CNS side effects of EFV may persist in patients thought to tolerate the drug [abstract WePpB1376]. XIII International Conference on AIDS; 2000 Jul 9-14; Durban.
95. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15: 71-5